Published in:
01-09-2007 | Editorial
Nice insulins, pity about the evidence
Authors:
F. Holleman, E. A. M. Gale
Published in:
Diabetologia
|
Issue 9/2007
Login to get access
Excerpt
In February 2006 the German Institute for Quality and Efficiency in Healthcare (IQWiG), an independent body with a mandate to assess the evidence for medical interventions, released its final report on the use of short-acting insulin analogues in the treatment of type 2 diabetes. The report found no advantage over soluble (regular) human insulin. Given that analogues cost more than soluble insulin, the report concluded that there was no evidence to support their use in patients with type 2 diabetes [
1]. A subsequent report concluded that the benefits of short-acting analogues in type 1 diabetes were marginal at best [
2], and a report on the long-acting analogues is on its way: many suspect that this will be almost equally negative. …